Glenmark Expands U.S. Injectable Portfolio with Launch of Ropivacaine Hydrochloride Injection

Image Source: Franchise India

Glenmark Pharmaceuticals Inc., USA, is set to launch Ropivacaine Hydrochloride Injection USP in three strengths—40 mg/20 mL, 150 mg/30 mL, and 200 mg/20 mL—starting November 2025. The product is a generic equivalent to Naropin and will support surgical anesthesia and pain management across U.S. healthcare settings.

Glenmark Pharmaceuticals Inc., the U.S. subsidiary of Glenmark Pharmaceuticals Ltd, has announced the upcoming launch of Ropivacaine Hydrochloride Injection USP in the American market. The injectable will be available in three single-dose vial strengths: 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL). Distribution is scheduled to begin in November 2025.

This launch marks a significant addition to Glenmark’s growing injectable portfolio and reinforces its commitment to providing affordable, high-quality alternatives in the U.S. healthcare market. The product has been approved as bioequivalent and therapeutically equivalent to Naropin® Injection, marketed by Fresenius Kabi USA, LLC.

Ropivacaine Hydrochloride is a long-acting local anesthetic used for surgical anesthesia, labor pain relief, and acute pain management. The launch is expected to enhance Glenmark’s presence in the hospital and surgical care segment, where demand for cost-effective anesthetic solutions continues to rise.

Key Highlights:

Product Launch: Glenmark will introduce Ropivacaine Hydrochloride Injection USP in three strengths for U.S. distribution starting November 2025.
Therapeutic Use: The drug is used for local or regional anesthesia during surgery, labor, and acute pain episodes.
Regulatory Approval: The injectable is bioequivalent and therapeutically equivalent to Naropin®, ensuring clinical efficacy and safety.
Strategic Expansion: This move strengthens Glenmark’s injectable offerings in North America, a key growth market.
Leadership Insight: Marc Kikuchi, President & Business Head, North America, noted the launch reflects Glenmark’s dedication to delivering affordable, high-quality medications to patients in need.

This development underscores Glenmark’s strategic focus on expanding its U.S. generics portfolio, particularly in the hospital injectable segment.

Sources: Business Standard, CNBC TV18, Rediff Money

Stay Ahead – Explore Now! Leadership Change At Aksh Optifibre: CFO Nikhil Jain Steps Down Amid Strategic Restructuring